Straits Times Index
3,187.66 +32.97 (+1.05%) S&P 500
5,033.76 +11.55 (+0.23%) Dow
37,860.68 +107.37 (+0.28%) Nasdaq
15,710.20 +26.83 (+0.17%) Bitcoin USD
63,575.57 +3,432.97 (+5.71%) CMC Crypto 200
885.54 0.00 (0.00%)
AstraZeneca PLC (AZN.L)
| Previous close | 10,862.00 |
| Open | 10,946.00 |
| Bid | 10,910.00 x 0 |
| Ask | 10,918.00 x 0 |
| Day's range | 10,858.00 - 11,018.00 |
| 52-week range | 9,461.00 - 12,348.00 |
| Volume | |
| Avg. volume | 2,898,752 |
| Market cap | 169.192B |
| Beta (5Y monthly) | 0.19 |
| PE ratio (TTM) | 35.67 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 2.28 (2.10%) |
| Ex-dividend date | 22 Feb 2024 |
| 1y target est | N/A |
- Business Wire
IMFINZI® (durvalumab) plus chemotherapy doubled overall survival rate at three years for patients with advanced biliary tract cancer in TOPAZ-1 Phase III trial
WILMINGTON, Del., April 16, 2024--Updated exploratory results from the TOPAZ-1 Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab) in combination with standard-of-care chemotherapy demonstrated a clinically meaningful long-term overall survival (OS) benefit at three years for patients with advanced biliary tract cancer (BTC).
- Business Wire
FASENRA approved for treatment of children aged 6 to 11 with severe asthma
WILMINGTON, Del., April 11, 2024--AstraZeneca’s FASENRA® (benralizumab) is now approved by the US Food and Drug Administration (FDA) for add-on maintenance treatment for patients with severe asthma aged 6 to 11 with an eosinophilic phenotype.1 FASENRA was first approved in 2017 as an add-on maintenance for the treatment of severe eosinophilic asthma (SEA) in patients aged 12 and older.1
- Business Wire
ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2 Positive Solid Tumors
TOKYO & BASKING RIDGE, N.J., April 06, 2024--ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2+ Solid Tumors
